Targeting cancer cells by exploiting their resistance

被引:49
作者
Blagosklonny, MV [1 ]
机构
[1] New York Med Coll, Brander Canc Res Inst, Hawthorne, NY 10532 USA
关键词
D O I
10.1016/S1471-4914(03)00111-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cancer cells are intrinsically resistant to growth arrest and can further acquire multidrug resistance. Current approaches to this problem are intended to reverse, overcome or prevent the drug resistance. However, the resistance of cancer cells can be exploited to kill resistant cells selectively, while sparing sensitive normal cells. As the simplest example, multidrug-resistant cells pump out protectors, such as pharmacological inhibitors of apoptosis. A sequence of at least two agents must include an exclusive protector, which is ineffective in resistant cancer cells, and an inclusive cytotoxic drug, which kills unprotected cells. By abolishing several dose-limiting side effects of chemotherapy, this strategy provides a means to treat selectively most deranged, aggressive and resistant cancers.
引用
收藏
页码:307 / 312
页数:6
相关论文
共 51 条
[1]   Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family [J].
Bishop, PC ;
Myers, T ;
Robey, R ;
Fry, DW ;
Liu, ET ;
Blagosklonny, MV ;
Bates, SE .
ONCOGENE, 2002, 21 (01) :119-127
[2]   Cyclotherapy Protection of Normal Cells and Unshielding of Cancer Cells [J].
Blagosklonny, Mikhail V. ;
Darzynkiewicz, Zbigniew .
CELL CYCLE, 2002, 1 (06) :375-382
[3]   Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs [J].
Blagosklonny, MV ;
Robey, R ;
Bates, S ;
Fojo, T .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (04) :533-539
[4]   Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal [J].
Blagosklonny, MV .
LEUKEMIA, 1999, 13 (12) :2031-2035
[5]   Flavopiridol inversely affects p21WAF1/CIP1 and p53 and protects p21-sensitive cells from paclitaxel [J].
Blagosklonny, MV ;
Darzynkiewicz, Z ;
Figg, WD .
CANCER BIOLOGY & THERAPY, 2002, 1 (04) :420-425
[6]   A new science-business paradigm in anticancer drug development [J].
Blagosklonny, MV .
TRENDS IN BIOTECHNOLOGY, 2003, 21 (03) :103-106
[7]   Oncogenic resistance to growth-limiting conditions [J].
Blagosklonny, MV .
NATURE REVIEWS CANCER, 2002, 2 (03) :221-225
[8]   Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs [J].
Blagosklonny, MV .
ONCOGENE, 2002, 21 (41) :6249-6254
[9]   Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs [J].
Blagosklonny, MV .
LEUKEMIA, 2002, 16 (04) :455-462
[10]   Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells [J].
Blagosklonny, MV .
LEUKEMIA, 2001, 15 (06) :936-941